Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.
Stevenson SM, Lowrance WT. Epidemiology and diagnosis of testis cancer. Urol Clin North Am. 2015;42(3):269–75. https://doi.org/10.1016/j.ucl.2015.04.001.
Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MA, Bokemeyer C. Testicular germ cell tumours. Lancet. 2016;387(10029):1762–74. https://doi.org/10.1016/S0140-6736(15)00991-5.
••Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol. 2019;202(2):272–81. https://doi.org/10.1097/JU.0000000000000318. (American Urological Association guideline for the diagnosis and treatment of early stage testicular cancer).
Capelouto CC, Clark PE, Ransil BJ, Loughlin KR. A review of scrotal violation in testicular cancer: Is adjuvant local therapy necessary? J Urol. 1995;153(3 Pt 2):981–5.
Patel HD, Gupta M, Cheaib JG, Sharma R, Zhang A, Bass EB, et al. Testis-sparing surgery and scrotal violation for testicular masses suspicious for malignancy: a systematic review and meta-analysis. Urol Oncol. 2020;38(5):344–53. https://doi.org/10.1016/j.urolonc.2020.02.023.
Leibovitch I, Little JS Jr, Foster RS, Rowland RG, Bihrle R, Donohue JP. Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. J Urol. 1996;155(3):952–4.
Article CAS PubMed Google Scholar
Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010;28(20):3388–404. https://doi.org/10.1200/JCO.2009.26.4481.
Article CAS PubMed Google Scholar
Oldenburg J, Berney DM, Bokemeyer C, Climent MA, Daugaard G, Gietema JA, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(4):362–75. https://doi.org/10.1016/j.annonc.2022.01.002.
Article CAS PubMed Google Scholar
••Patrikidou A, Cazzaniga W, Berney D, Boormans J, de Angst I, Nardo D, et al. European association of urology guidelines on testicular cancer: 2023 update. Eur Urol. 2023. https://doi.org/10.1016/j.eururo.2023.04.010. (European association of urology guideline based on the most recent evidence on the diagnosis, therapy, and follow-up of testicular cancer).
•Leao R, Albersen M, Looijenga LHJ, Tandstad T, Kollmannsberger C, Murray MJ, et al. Circulating MicroRNAs, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review. Eur Urol. 2021;80(4):456–66. https://doi.org/10.1016/j.eururo.2021.06.006. (Systemic review for clinical applications of serum levels of microRNAs in adult testicular germ cell tumors).
Article CAS PubMed Google Scholar
Dieckmann KP, Radtke A, Spiekermann M, Balks T, Matthies C, Becker P, et al. Serum levels of MicroRNA miR-371a-3p: a sensitive and specific new biomarker for germ cell tumours. Eur Urol. 2017;71(2):213–20. https://doi.org/10.1016/j.eururo.2016.07.029.
Article CAS PubMed Google Scholar
Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washingon MK, et al. AJCC cancer staging manual. 8th ed. New York: Springer; 2017. p. 327–32.
International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15(2):594–603. https://doi.org/10.1200/JCO.1997.15.2.594.
Gillessen S, Sauve N, Collette L, Daugaard G, de Wit R, Albany C, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium. J Clin Oncol. 2021;39(14):1563–74. https://doi.org/10.1200/JCO.20.03296.
Article CAS PubMed PubMed Central Google Scholar
Beyer J, Collette L, Sauve N, Daugaard G, Feldman DR, Tandstad T, et al. Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium. J Clin Oncol. 2021;39(14):1553–62. https://doi.org/10.1200/JCO.20.03292.
Article CAS PubMed PubMed Central Google Scholar
Canete Portillo S, Rais-Bahrami S, Magi-Galluzzi C. Updates in 2022 on the staging of testicular germ cell tumors. Hum Pathol. 2022;128:152–60. https://doi.org/10.1016/j.humpath.2022.07.009.
Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol. 1982;128(2):315–20. https://doi.org/10.1016/s0022-5347(17)52904-3.
Article CAS PubMed Google Scholar
Stephenson AJ, Sheinfeld J. The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urol Oncol. 2004;22(3):225–33. https://doi.org/10.1016/j.urolonc.2004.04.029.
Sogani PC. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. Urol Clin North Am. 1991;18(3):561–73.
Article CAS PubMed Google Scholar
••Hiester A, Che Y, Lusch A, Kuss O, Niegisch G, Lorch A, et al. Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA/B (PRIMETEST). Eur Urol. 2022. https://doi.org/10.1016/j.eururo.2022.10.021. (Evaluated the role of primary RPLND in patients with primary clinical stage IIA/B or recurrent clinical stage I seminoma with unilateral retroperitoneal lymph node metastases <5 cm without adjuvant therapy).
••Daneshmand S, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, et al. Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy. J Clin Oncol. 2023;41(16):3009–18. https://doi.org/10.1200/JCO.22.00624. (Evaluated the role of primary RPLND in patients with pure testicular seminoma, either stage 1 with an isolated 1–3 cm relapse or stage 2 with no more than 2 lymph nodes measuring 1–3 cm in any dimension within the RPLND template).
Article CAS PubMed Google Scholar
•Heidenreich A, Seelemeyer F, Paffenholz P, Pfister DA. Interim analysis of the prospective COTRIMS (cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial. J Clin Oncol. 2023;41(6 suppl):409. https://doi.org/10.1200/JCO.2023.41.6_suppl.409. (The interim results of the COTRIMS trial were presented at the 2022 American society of clinical oncology symposium. A total of 30 patients with marker negative clinical stage IIA and IIB classical seminoma of the testis underwent modified unilateral template RPLND without adjuvant therapy).
•Cazzaniga WKN, Reid A, Huddart R, Mayer E, Nicol D. Outcomes of minimally invasive retroperitoneal lymph node dissection (Primary MI- RPLND) followed by adjuvant carboplatin (AUC7) for clinical stage IIa/b seminoma. Eur Urol. 2023;83:S1065. https://doi.org/10.1016/S0302-2838(23)00794-7. (A total of 54 patients with stage IIA/B seminoma were treated with modified unilateral template minimally invasive RPLND and adjuvant carboplatin. Data was presented at the EAU 2023 annual meeting).
Ehrlich Y, Brames MJ, Beck SD, Foster RS, Einhorn LH. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol. 2010;28(4):531–6. https://doi.org/10.1200/JCO.2009.23.0714.
Article CAS PubMed Google Scholar
Ravi P, Gray KP, O’Donnell EK, Sweeney CJ. A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor. Ann Oncol. 2014;25(2):331–8. https://doi.org/10.1093/annonc/mdt425.
Article CAS PubMed Google Scholar
Carver BS, Bianco FJ Jr, Shayegan B, Vickers A, Motzer RJ, Bosl GJ, et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2006;176(1):100–3. https://doi.org/10.1016/S0022-5347(06)00508-8.
Jewett MA, Torbey C. Nerve-sparing techniques in retroperitoneal lymphadenectomy in patients with low-stage testicular cancer. Semin Urol. 1988;6(3):233–7.
Beck SD, Bey AL, Bihrle R, Foster RS. Ejaculatory status and fertility rates after primary retroperitoneal lymph node dissection. J Urol. 2010;184(5):2078–80. https://doi.org/10.1016/j.juro.2010.06.146.
Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones J, Geier G. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol. 1990;144(2 pt 1):287–91. https://doi.org/10.1016/s0022-5347(17)39434-x.
Article CAS PubMed Google Scholar
Pettus JA, Carver BS, Masterson T, Stasi J, Sheinfeld J. Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology. 2009;73(2):328–31. https://doi.org/10.1016/j.urology.2008.08.501.
Jewett MA, Kong YS, Goldberg SD, Sturgeon JF, Thomas GM, Alison RE, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol. 1988;139(6):1220–4. https://doi.org/10.1016/s0022-5347(17)42869-2.
Article CAS PubMed Google Scholar
Donohue JP, Roth LM, Zachary JM, Rowland RG, Einhorn LH, Williams SG. Cytoreductive surgery for metastatic testis cancer: tissue analysis of retroperitoneal masses after chemotherapy. J Urol. 1982;127(6):1111–4. https://doi.org/10.1016/s0022-5347(17)54256-1.
Article CAS PubMed Google Scholar
Richie JP. Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol. 1990;144(5):1160–3. https://doi.org/10.1016/s0022-5347(17)39681-7.
Article CAS PubMed Google Scholar
Do
Comments (0)